抄録
The effectiveness of a new antileukemic agent, 6-mercaptopurine riboside (Thioinosine) on acute myelogenous leukemia (AML) was studied.
Forty-two patients (19 males and 23 females) including 34 cases with AML were given 45 courses of Thioinosine administration in combination with glucocorticoids (GC). Fifty-five patients (27 males and 28 females) including 54 cases with AML were treated with 6-mercaptopurine (6 MP) plus GC and served as control. The average daily doses of Thioinosine and 6 MP were 300 mg (50∼400 mg) and 100 mg (30∼150 mg) respectively.
The rate of remission at the initial treatment with Thioinosine plus GC was 82.2%, whereas that with 6 MP plus GC was 62.9%. The rate of remission after second trials was 30% with Thioinosine plus GC, and 40% with 6 MP plus GC. The number of cases in theses studies, however, was too small to draw statistically significant differences between the two treatment groups (p>0.05).
In average, 42 days were required to induce initial remission with Thioinosine and 44.2 days with 6 MP.
From these data, it was suggested that the effectiveness of Thioinosine in treatment of AML was as potent as 6 MP.
One of the most frequent side effects of Thioinosine and 6 MP were liver impairment (36.5% and 22.6% respectively). The development of this side effect with Thioinosine seemed to come some what earlier thanwith 6 MP.
